Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Xilio Therapeutics Inc (XLO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.71+0.35%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for XLO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient cash and manage debt | A supporting condition in Xilio Therapeutics Inc's published investment case. The stated target is Cash reserves sufficient to fund operations through next 12 months without dilution. | Intact | Cash reserves fall below operational needs requiring dilutive financing | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
XLO is a high-risk, loss-making biotechnology company whose longer-term case depends on clinical progress and collaboration income. The thesis has improved mildly after two reported earnings beats, but recent financial performance remains weak relative to its industry cohort.
The valuation evidence points to XLO being cheap versus peers, with a negative expectations gap, but confidence in that assessment is low. The priced-in signal is classified as justified, with no fragility warning; the evidence does not show that weak fundamentals have been resolved.
Near term, results remain vulnerable: the estimated miss probability is 43%, and a guidance cut at the next call is a stated risk. Over the multi-year view, management is advancing XTX501 and other masked therapy programs, while collaboration revenue has grown; cash declined from the first to the second quarter of 2026, and the stated runway extends into early 2028 with milestone payments and possible warrant exercises.
The thesis hinges on continued pipeline progress, collaboration income, and maintaining enough cash to fund operations into early 2028. Near-term setbacks could include lower guidance or further job-market weakening, which may weigh on cyclical and healthcare names; continued earnings strength and higher guidance from healthcare bellwethers would support sector momentum.
For the next 1 to 3 years, XLO remains a watch-stage, high-risk biotech case with active pipeline work and growing collaboration revenue, but weak financial performance and uncertain funding conditions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce losses and improve EPS trajectory |
| A primary condition in Xilio Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -$3.02 in FY26 to less negative by FY27. |
| Intact |
| EPS loss worsens beyond -$3.02 in FY26 or remains flat without improvement in FY27 |
Diluted EPS: $-0.33 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$3.02 in FY26 to less negative by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.33 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain or improve revenue trajectory | A primary condition in Xilio Therapeutics Inc's published investment case. The stated target is Revenue stabilizes at or above $12.65M per quarter over the next 4 quarters. | Intact | Quarterly revenue falls below $12.65M consistently over two consecutive quarters | Revenue: $18.692M FY2026-Q2; GAAP. Published target: Revenue stabilizes at or above $12.65M per quarter over the next 4 quarters. Target period is not explicitly aligned with this observation. Aug 12, 202618,692,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.59 → $-1.98 · observed estimates
$0.03B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-25 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-26 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-27 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-28 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-29 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-30 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-07-31 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-01 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-02 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-03 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-04 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-05 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-06 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-08 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-09 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-10 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-12 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-13 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-14 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-15 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-16 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-17 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-18 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-19 | $-2.59 | $28,550,000 | 1 / 1 |
| 2026-08-20 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-21 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-22 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-23 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-24 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-25 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-26 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-27 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-28 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-29 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-30 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-08-31 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-01 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-02 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-03 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-04 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-05 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-06 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-07 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-08 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-09 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-10 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-11 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-12 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-13 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-14 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-15 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-16 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-17 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-18 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-19 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-20 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-21 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-22 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-23 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-24 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-25 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-26 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-27 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-28 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-29 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-09-30 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-01 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-02 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-03 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-04 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-05 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-06 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-07 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-08 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-09 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-10 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-11 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-12 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-13 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-14 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-15 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-16 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-17 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-18 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-19 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-20 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-21 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-22 | $-2.23 | $26,530,000 | 1 / 1 |
| 2026-10-23 | $-1.99 | $49,515,000 | 1 / 1 |
| 2026-10-24 | $-1.99 | $49,515,000 | 1 / 1 |
| 2026-10-25 | $-1.99 | $49,515,000 | 1 / 1 |
| 2026-10-26 | $-1.99 | $49,515,000 | 1 / 1 |
| 2026-10-27 | $-1.99 | $49,515,000 | 1 / 1 |
| 2026-10-28 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-10-29 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-10-30 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-10-31 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-11-01 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-11-02 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-11-03 | $-1.98 | $49,515,000 | 1 / 1 |
| 2026-11-04 | $-1.98 | $49,515,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.